Eylea fast-tracking through second NICE appraisal
This article was originally published in Scrip
NICE, the health technology appraisal institute for England and Wales, has issued positive final draft guidance for Bayer's Eylea (aflibercept solution for intravitreal injection, or VEGF Trap-Eye) in a second indication: visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO). This recommendation also marks the second time Eylea has received a draft Final Appraisal Determination (FAD) without the need for additional consultation.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.